Asthma
Conditions
Keywords
asthma, allergen challenge
Brief summary
This is a study investigating whether 14 days of dosing with GW274150 has a beneficial effect on a model of asthma type inflammation called the allergen-induced late asthmatic response. This will be compared with the response after treatment with a dummy (placebo) and a tablet treatment for asthma called Singulair (montelukast). Subjects in the study will receive all 3 treatments in a random order. The study is double-blind so subjects will not know which treatment they are taking at any given time.
Interventions
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Mild asthma: taking reliever medication (e.g. salbutamol) only. * Screening involves measuring responses to the lung challenge agents: allergen, AMP, and methacholine. Only those with specific types of response to these will be eligible for the study.
Exclusion criteria
* Recent steroid treatment. * Significant illnesses or diseases other than asthma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect on the late asthmatic reaction following an inhaled allergen challenge | Up to Day 115 |
Secondary
| Measure | Time frame |
|---|---|
| Measures of safety. Measures of lung function | Up to Day 115 |
Countries
United Kingdom
Outcome results
None listed